Physician profile
Ralph E Oursler
NPI 1689637613
$8,013.49
in general payments reported to CMS, 2019-2025
23 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $4,287 · 2021: $249 · 2022: $133 · 2023: $670 · 2024: $642 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $2,113.32 | 2019-2021 | |
| Lensar, INC. | $2,112.13 | 2020-2025 | Lensar Laser System |
| Alcon Vision LLC | $1,738.71 | 2019-2025 | Clareon, Wavelight Refractive Suite, Ngenuity |
| Johnson & Johnson Surgical Vision, INC. | $709.37 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Rxsight INC | $290.24 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $256.82 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $142.65 | 2023-2024 | Miebo, Xiidra |
| Eyepoint US, INC. | $90.15 | 2019 | |
| Thea Pharma INC. | $83.89 | 2023-2024 | Iyuzeh |
| Allergan, INC. | $83.08 | 2019-2021 | |
| Beaver-Visitec International, INC. | $64.61 | 2020 | |
| Rayner Intraocular Lenses Limited | $60.68 | 2023-2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Alcon Research LLC | $43.74 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $38.64 | 2025 | Xdemvy |
| Shire North American Group INC | $31.77 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $23.32 | 2019 | |
| Aerie Pharmaceuticals, INC. | $22.19 | 2019 | |
| Dompe US, INC. | $21.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.56 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.89 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $18.88 | 2023 | Veracity Surgical |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.63 | 2019 | |
| Harrow Eye, LLC | $14.24 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Oursler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.